CROSSJECT (EPA:ALCJ) | WebDisclosure

PRESS RELEASE

published on 06/24/2025 at 19:00, 1 year ago

CROSSJECT annonce le vif succès de son augmentation de capital portée à 5,7 millions d’euros après exercice intégral de la clause d’extension
CROSSJECT annonce le vif succès de son augmentation de capital à 5,7 millions d’euros après exercice intégral de la clause d’extension pour ZEPIZURE®

Financement Augmentation De Capital Pharmaceutique Crossject ZEPIZURE
PRESS RELEASE

published on 06/24/2025 at 19:00, 1 year ago

CROSSJECT announces a successful capital increase of €5.7 million following full exercise of the extension clause
CROSSJECT successfully completes a capital increase of €5.7 million through preferential subscription rights, benefiting from new investor support and Gemmes Venture, to advance ZEPIZURE® development

Capital Increase Crossject ZEPIZURE® Gemmes Venture Vatel Capital
BRIEF

published on 06/11/2025 at 07:35, 1 year 1 month ago

CROSSJECT advances in the development of ZEPIZURE® Junior for children

Epilepsy Pediatrics Crossject Auto-injector ZEPIZURE Junior
BRIEF

published on 06/11/2025 at 07:35, 1 year 1 month ago

CROSSJECT progresse dans le développement de ZEPIZURE® Junior pour enfants

Pédiatrie Crossject Auto-injecteur Épilepsie ZEPIZURE Junior
PRESS RELEASE

published on 06/11/2025 at 07:30, 1 year 1 month ago

CROSSJECT advances on the development of ZEPIZURE® Junior, its solution for epilepsy crises in children
CROSSJECT advances development of ZEPIZURE® Junior for epilepsy crises in children, completing clinical studies for effective calibration and injection depth validation

Epilepsy Clinical Studies Crossject ZEPIZURE® Junior Pediatric Population
PRESS RELEASE

published on 06/11/2025 at 07:30, 1 year 1 month ago

CROSSJECT avance sur le développement de ZEPIZURE® Junior, sa solution pour les crises d'épilepsie chez l'enfant
CROSSJECT progresse dans le développement de ZEPIZURE® Junior pour les crises d'épilepsie chez l'enfant, avec calibration réussie de ZENEO®. Étude clinique menée pour adapter l'injection aux enfants

Crossject Enfant ZENEO® Épilepsie ZEPIZURE® Junior
BRIEF

published on 06/06/2025 at 17:50, 1 year 1 month ago

Publication des droits de vote et actions de Crossject

Droits De Vote Capital Social Actions AMF Crossject
BRIEF

published on 06/06/2025 at 17:50, 1 year 1 month ago

Publication of Crossject voting rights and shares

Share Capital Voting Rights Actions AMF Crossject
PRESS RELEASE

published on 06/06/2025 at 17:45, 1 year 1 month ago

Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social
CROSSJECT publie le nombre total de droits de vote et d'actions au 31 mai 2025, incluant les informations sur son capital social et ses activités pharmaceutiques

Droits De Vote Capital Social Pharmaceutique Crossject Urgence
BRIEF

published on 06/04/2025 at 20:26, 1 year 1 month ago

CROSSJECT lance une augmentation de capital de près de 5 millions d'euros

Investissement Augmentation De Capital Pharmaceutique Droit Préférentiel De Souscription ZEPIZURE®

Published on 07/14/2026 at 01:45, 6 hours 6 minutes ago

Arctic Fox Lithium Approved for Trading on the OTCQB Venture Market and Announces DTC Eligibility
Published on 07/14/2026 at 00:01, 7 hours 50 minutes ago

Captor Capital Announces Delay in its Annual Filings
Published on 07/13/2026 at 23:10, 8 hours 41 minutes ago

Galaxy Ventures Inc. Announces Director Resignation
Published on 07/13/2026 at 21:35, 10 hours 16 minutes ago

ATHA Energy Announces Corporate Activities Update
Published on 07/13/2026 at 20:00, 11 hours 51 minutes ago

IBC Announces Share-Based Compensation to Directors

View all ACCESSWIRE

Published on 07/14/2026 at 07:47, 4 minutes ago

EQS-Adhoc: DATA MODUL Aktiengesellschaft Produktion und Vertrieb von elektronischen Systemen:
Published on 07/14/2026 at 07:30, 21 minutes ago

REINET INVESTMENTS S.C.A. SHARE BUYBACK PROGRAMME – UPDATE 14 July 2026
Published on 07/14/2026 at 07:30, 21 minutes ago

SFC Energy AG secures CAD 3.1 million follow-up order from North American mobile surveillance solutions provider
Published on 07/14/2026 at 07:30, 21 minutes ago

Bastei Lübbe with higher revenues in tandem with reduced profitability in a difficult market environment
Published on 07/14/2026 at 07:00, 51 minutes ago

The Swiss are confident about the future despite acknowledging some areas of concern

View all EQS

Published on 07/13/2026 at 18:00, 13 hours 51 minutes ago

CP Icade - Icade reprend 100% de la propriété de la Tour Eqho à la Défense
Published on 07/13/2026 at 18:00, 13 hours 51 minutes ago

PR Icade - Icade regains full ownership of the Eqho Tower in La Défense
Published on 07/13/2026 at 18:00, 13 hours 51 minutes ago

THERMADOR GROUPE : 2026 half-year turnover
Published on 07/13/2026 at 18:00, 13 hours 51 minutes ago

THERMADOR GROUPE : publication du chiffre d'affaires semestriel 2026
Published on 07/13/2026 at 17:45, 14 hours 6 minutes ago

Weekly share buyback

View all LES ECHOS COMFI WIRE

News